Zuzana Zelinková, Jozef Baláž, Eva Goncalvesová, Miloš Greguš, Tibor Hlavatý, Milan Hlista, Martin Huorka, Juraj Chudej, Miloš Jeseňák, Barbora Kadlečková, Ľubomír Lisý, Ivan Solovič, Mária Zakuciová
Systemic immune suppressive therapy of inflammatory bowel disease (IBD) interferes with immune responses at various
levels. This interference may lead to an increased risk of infectious, oncological, neurological and cardiovascular
complications of IBD treatment. Selection of IBD patients at risk of development of these complications may help to
increase the safety of the treatment of this chronic invalidating disorder. This review aims to provide a profile of an IBD
patient at risk of complications of systemic immune suppression.